

Antibacterial Activity Against Sensitive and Resistant bacteria of Organic salts and Ionic Liquids based on β -lactam Antibiotics and Their Hydrolysates

Ricardo Ferraz^{1,2,*}, Dário Silva³, Ana Rita Dias^{1,2}, Vitorino Dias¹, Miguel M. Santos³, Luís Pinheiro³, Cristina Prudêncio^{1,4}, João Paulo Noronha³,
 Željko Petrovski^{3,*} and Luís C. Branco^{3,*}

¹ Ciências Químicas e das Biomoléculas (CQB) e Centro de Investigação em Saúde e Ambiente (CISA), Escola Superior de Saúde do Instituto Politécnico do Porto, 4400-330 Porto, Portugal; ² LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre 687, 4169-007 Porto, Portugal; ³ LAQV-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, 2829-516 Caparica, Portugal; ⁴ i3S, Instituto de Inovação e Investigação em Saúde, Universidade do Porto, 4099-002 Porto, Portugal, E-mail: z.petrovski@fct.unl.pt

Introduction

Organic salts and ionic Liquids (OSILs) containing active pharmaceutical ingredients (OSIL-APIs) have been presented as good drug delivery tool for APIs and drug modulations [1-3]. Our group described the suitable combination of pharmaceutical drugs and counter-ions as an innovative approach to improve the original bioavailability, reduce polymorphism as well as enhanced the therapeutic effect [1,2]. Herein, the synthesis and activity of some antimicrobial OSIL-APIs containing amoxicillin and penicillin in the hydrolysate form of β -lactam antibiotics as well as ciprofloxacin and norfloxacin as fluoroquinolone antibiotics [4,5].

β -Lactam hydrolysates derived OSIL-APIs

Ampicillin derived OSIL-APIs

Ionic liquids and organic salts based on the ammonia hydrolysate anion of penicillin G and amoxicillin (α -amide of benzyl penicilloic acid and of amoxicillin penicilloic acid, respectively), abbreviated here as [seco-Pen] and [seco-Amx], respectively, were prepared by an ammonia buffered reaction procedure that was recently developed by our group [6].





Figure 1 – Synthesis of OSIL-APIs based on ammonia hydrolysate of amoxicillin and penicillin

Ampicillin based organic salts and ionic liquids were prepared in good yield using buffer neutralization method [6] (see Figure 2). Except two (choline and C₂OHMIM) they are all ionic liquids as their m.p. are below 100 °C.



Ampicillin based IL-APIs were first tested against sensitive gram-positive and sensitive and resistant gram-negative bacteria (Table 3 and 4). The activity of prepared compounds was compared with standard antibiotic [Na][Amp].

Table 3 – Antimicrobial activity of ampicillin based IL-APIs against gram sensitive bacteria expressed as RDIC

Strains	Gram-negative		Gram-positive		
	<i>E. coli</i> ATCC 25922	<i>K. pneumoniae</i>	<i>S. aureus</i> ATCC 25923	<i>E. fecalis</i>	<i>S. epidermis</i>
Comp.					
Na[Amp]	1	1	1	1	1
[P _{6,6,6,14}][Amp]	0.02	0.5	0.1	1	1
[C ₁₆ Pyr][Amp]	0.1	50	1	10	10
[C ₂ OHMIM][Amp]	0.01	-	-	0.01	0.02

The novel β -Lactam hydrolysates derived OSIL-APIs were tested against sensitive and resistant bacteria (Table 1 and 2). The activity of prepared compounds was compared with standard antibiotics and their hydrolysates [Na][seco-Amx], [K][Pen] and [K][seco-Pen].

Table 1 – Antimicrobial activity of ammonia hydrolysed penicillin and amoxicillin based OSIL-APIs expressed as Minimum inhibitory concentrations (MICs in mM) and Relative Decrease of Inhibitory Concentration (RDIC)

Compound	<i>S. aureus</i> ATCC25923	RDIC	<i>E. coli</i> ATCC25922	RDIC
Amx	0.050	1	0.005	1
Na[seco-Amx]	>5.0	<0.01	>5.0	<0.001
[EMIM][seco-Amx]	5.0	0.01	2.5	0.002
[C ₂ OHMIM][seco-Amx]	0.050	1	5.0	0.001
[Choline][seco-Amx]	>5.0	<0.01	>5.0	<0.001
[P _{6,6,6,14}][seco-Amx]	>5.0	<0.01	0.5	0.01
[C ₁₆ Pyr][seco-Amx]	>5.0	<0.01	0.050	0.1
K[Pen]	0.500	1	0.500	1
K[seco-Pen]	>5.0	<0.1	>5.0	<0.1
[EMIM][seco-Pen]	>5.0	<0.1	>5.0	<0.1
[C ₂ OHMIM][seco-Pen]	0.005	100	>5.0	<0.1
[Choline][seco-Pen]	>5.0	<0.1	5.0	0.1
[TEA][seco-Pen]	>5.0	<0.1	0.050	10
[P _{6,6,6,14}][seco-Pen]	>5.0	<0.1	>5.0	<0.1
[C ₁₆ Pyr][seco-Pen]	>5.0	<0.1	>5.0	0.1

$$RDIC(OSIL-API) = MIC(API) / MIC(OSIL-API)$$

Table 4 – Minimum inhibitory concentrations (mM) and relative decrease of inhibitory concentration (RDIC) of the compounds derivate of ampicillin that were produced on resistant strains.

Comp.	Strains	<i>E. coli</i> TEM CTX M9		<i>E. coli</i> CTX M2		<i>E. coli</i> AmpC Mox2	
		MIC	RDIC	MIC	RDIC	MIC	RDIC
Na[Amp]		>5	1	>5	1	>5	1
[P _{6,6,6,14}][Amp]		0.5	>10	0.5	>10	>5	-
[C ₁₆ Pyr][Amp]		0.005	>1000	0.05	>100	>5	-
[TEA][Amp]		>5	-	>5	-	>5	-
[cholin][Amp]		>5	-	>5	-	>5	-
[EMIM][Amp]		>5	-	>5	-	>5	-
[C ₂ OHMIM][Amp]		>5	-	>5	-	5	>1

Table 2 – Minimum inhibitory concentrations (mM) and relative decrease of inhibitory concentration (RDIC) of the new compounds derivate of penicillin and amoxicillin that were produced on resistant strains.

Compound	<i>E. Coli</i> CTX M9	RDIC	<i>E. coli</i> CTX M2	RDIC	MRSA ATCC 43300	RDIC
Amx	>5	1	>5	1	>5	1
Na[seco-Amx]	>5	-	>5	-	>5	-
[EMIM][seco-Amx]	>5	-	>5	-	>5	-
[C ₂ OHMIM][seco-Amx]	>5	-	>5	-	5	>1
[P _{6,6,6,14}][seco-Amx]	0.05	>100	1.0	>5	>5	-
[C ₁₆ Pyr][seco-Amx]	0.05	>100	0.05	>100	0.005	>1000
[Choline][seco-Amx]	0.5	>10	0.05	>100	0.5	10
K[Pen]	>5	1	>5	1	>5	1
K[seco-Pen]	>5	-	>5	-	>5	-
[EMIM][seco-Pen]	>5	-	>5	-	>5	-
[C ₂ OHMIM][seco-Pen]	>5	-	>5	-	>5	-
[Choline][seco-Pen]	1.0	>5	>5	-	1.0	>5
[P _{6,6,6,14}][seco-Pen]	0.5	>10	0.5	>10	>5	-
[C ₁₆ Pyr][seco-Pen]	0.5	>10	0.5	>10	0.05	>100
[TEA][seco-Pen]	>5	-	>5	-	>5	-

Conclusions

The prepared OSIL-APIs derived from penicillin G, amoxicillin and ampicillin show enhanced activities against several bacteria strains, particularly against resistant ones. The RDIC prove to be a good tool to monitor effectiveness of OSIL-APIs in respect to parent antibiotics. In case of sensitive strains the activity of novel OSIL-APIs was usually not greatly increased but in case of resistant species the MICs at the nanomolar scale were measured, representing RDIC values as high as >1000. The cationic species were mostly ineffective when in the form of halide salts (not shown here). These results highlight OSIL-APIs as a promising solution to fight against antibiotic resistance.

Acknowledgements: This research was funded by by Fundação para a Ciência e Tecnologia through projects (PTDC/QUI-QOR/32406/2017, PEst-C/LA0006/2013, PTDC/CTM/103664/2008) and PTDC/BTM-SAL/29786/2017, and one contract under Investigador FCT (L.C.B.). ZP thanks to Fundação para a Ciência e a Tecnologia, MCTES, for the Norma transitória DL 57/2016 Program Contract. This work was also supported by the Associate Laboratory for Green Chemistry, which is financed by national funds from FCT/MEC (UIDB/50006/2013), UIDB/50006/2020 and co-financed by the ERDF under the PT2020 Partnership Agreement (POCI-01- 0145-FEDER-007265). The authors also thank Solchemar company for support.

References

- [1] Ferraz, et al. *RSC Adv.* **2014**, *4*, 4301-4307. [2] Marrucho I.M. et al. *Annual Rev. Chem. Biom. Eng.* **2014**, *5*, 527-546. [3] Mester, P. et al. *RSC Adv.* **2016**, *6*, 32220-32227. [4] Santos, M. M. et al. *Pharmaceutics* **2020**, *12*, 694. [5] Ferraz, R. et al. *Pharmaceutics* **2020**, *12*, 221. [6] Ferraz, R. et al., *MedChemComm* **2012**, *3*, 494-497.



6th International Electronic Conference on Medicinal Chemistry
1-30 November 2020

sponsored:



pharmaceuticals

